Imugene Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Leslie Chong
4.83yrs
Tenure
AU$1,153,580
Compensation
Ms. Leslie Chong serves as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21, 2016. Ms. Chon...
CEO Compensation Analysis
| Date | Total Comp. | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2022 | AU$1m | AU$600k | -AU$38m |
| Mar 31 2022 | n/a | n/a | -AU$33m |
| Dec 31 2021 | n/a | n/a | -AU$27m |
| Sep 30 2021 | n/a | n/a | -AU$23m |
| Jun 30 2021 | AU$789k | AU$408k | -AU$18m |
| Mar 31 2021 | n/a | n/a | -AU$15m |
| Dec 31 2020 | n/a | n/a | -AU$12m |
| Sep 30 2020 | n/a | n/a | -AU$11m |
| Jun 30 2020 | AU$733k | AU$375k | -AU$11m |
| Mar 31 2020 | n/a | n/a | -AU$10m |
| Dec 31 2019 | n/a | n/a | -AU$9m |
| Sep 30 2019 | n/a | n/a | -AU$8m |
| Jun 30 2019 | AU$777k | AU$350k | -AU$8m |
| Mar 31 2019 | n/a | n/a | -AU$7m |
| Dec 31 2018 | n/a | n/a | -AU$6m |
| Sep 30 2018 | n/a | n/a | -AU$5m |
| Jun 30 2018 | AU$403k | AU$300k | -AU$4m |
| Mar 31 2018 | n/a | n/a | -AU$3m |
| Dec 31 2017 | n/a | n/a | -AU$3m |
| Sep 30 2017 | n/a | n/a | -AU$3m |
| Jun 30 2017 | AU$337k | AU$290k | -AU$3m |
| Mar 31 2017 | n/a | n/a | -AU$3m |
| Dec 31 2016 | n/a | n/a | -AU$3m |
| Sep 30 2016 | n/a | n/a | -AU$3m |
| Jun 30 2016 | AU$323k | AU$229k | -AU$3m |
Compensation vs Market: Leslie's total compensation ($USD819.94K) is about average for companies of similar size in the Australian market ($USD1.06M).
Compensation vs Earnings: Leslie's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.25yrs | AU$350.00k | 4.94% A$ 46.0m | |
| CEO, MD & Executive Director | 6.17yrs | AU$1.15m | 1.2% A$ 11.2m | |
| Chief Technology Officer | no data | AU$490.82k | 0.29% A$ 2.7m | |
| Chief Business Officer | 1.58yrs | AU$1.62m | no data | |
| Chief Financial Officer | 0.33yr | no data | no data | |
| Senior Vice President of Clinical Operations | 1yr | no data | no data | |
| Chief Medical Officer | 0.25yr | no data | no data | |
| Joint Company Secretary | 1.08yrs | no data | no data |
1.0yrs
Average Tenure
Experienced Management: IMU's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.25yrs | AU$350.00k | 4.94% A$ 46.0m | |
| CEO, MD & Executive Director | 4.83yrs | AU$1.15m | 1.2% A$ 11.2m | |
| Independent Non-Executive Director | 7.33yrs | AU$83.41k | 0.35% A$ 3.3m | |
| Independent Non-Executive Director | 3.67yrs | AU$85.64k | 0.32% A$ 3.0m | |
| Chair of Oncolytic Virotherapy Scientific Advisory Board | 3.17yrs | no data | 0% A$ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 8.75yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.25yrs | no data | no data | |
| Scientific Advisory Board Member | 6.75yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.08yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.33yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.25yrs | no data | no data |
4.8yrs
Average Tenure
Experienced Board: IMU's board of directors are considered experienced (4.8 years average tenure).